Neuroinflammation
contributes to the pathogenesis of several neurodegenerative
disorders. Glycogen synthase kinase-3β (GSK-3β) regulates
the release of proinflammatory cytokines and promotes inflammatory
responses in immune cells. Microglia are the resident mononuclear
immune cells of the central nervous system. Here, we investigated
the anti-neuroinflammatory effects of (2S,3S,4R,5R,6S)-6-(2-(3,4-dimethoxyphenyl)-5,7-dimethoxy-4-oxo-4H-chromen-6-yl)-3,4,5-trihydroxy-N-((S)-1,1,1-trifluoropropan-2-yl)tetrahydro-2H-pyran-2-carboxamide
(TFGF-18), a semisynthetic GSK-3β inhibitor, in lipopolysaccharide
(LPS) activation of spontaneously immortalized SIM-A9 microglial cells
and of mouse cortical microglia. TFGF-18 at 2.5 μM concentration
inhibited LPS-induced production of nitric oxide by 56.3% and the
proinflammatory cytokines TNF-α and IL-1β by 28.3 and
59.2% in SIM-A9 cells, respectively, relative to the LPS treatment
control group. Pretreatment of mouse primary microglial cells with
TFGF-18 at 2.5 μM concentration led to a reduction of 58.7%
in TNF-α+ microglial cells at 24 h post-LPS stimulation. The
migration of LPS-activated SIM-A9 cells was also reduced by 26.7%
with pretreatment of TFGF-18 in a scratch assay. Analyses of signaling
pathways demonstrated that TFGF-18 led to the suppression of LPS-induced
GSK-3β activation and p65/NF-κB activity. Furthermore,
the co-culture of SIM-A9 with SH-SY5Y neuroblastoma cells showed the
suppression of TFGF-18 to microglia-mediated neurotoxicity in vitro.
The findings indicate strong inhibitory effects of TFGF-18 on LPS-induced
microglia activation via regulation of GSK-3β and downstream
p65/NF-κB signaling. The results suggest a potential role of
TFGF-18 in neuroprotection via its anti-neuroinflammatory effect.